Literature DB >> 20813282

Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction.

Barry A Borlaug1, Thomas P Olson, Carolyn S P Lam, Kelly S Flood, Amir Lerman, Bruce D Johnson, Margaret M Redfield.   

Abstract

OBJECTIVES: The purpose of this study was to comprehensively examine cardiovascular reserve function with exercise in patients with heart failure and preserved ejection fraction (HFpEF).
BACKGROUND: Optimal exercise performance requires an integrated physiologic response, with coordinated increases in heart rate, contractility, lusitropy, arterial vasodilation, endothelial function, and venous return. Cardiac and vascular responses are coupled, and abnormalities in several components may interact to promote exertional intolerance in HFpEF.
METHODS: Subjects with HFpEF (n = 21), hypertension without heart failure (n = 19), and no cardiovascular disease (control, n = 10) were studied before and during exercise with characterization of cardiovascular reserve function by Doppler echocardiography, peripheral arterial tonometry, and gas exchange.
RESULTS: Exercise capacity and tolerance were reduced in HFpEF compared with hypertensive subjects and controls, with lower VO(2) and cardiac index at peak, and more severe dyspnea and fatigue at matched low-level workloads. Endothelial function was impaired in HFpEF and in hypertensive subjects as compared with controls. However, blunted exercise-induced increases in chronotropy, contractility, and vasodilation were unique to HFpEF and resulted in impaired dynamic ventricular-arterial coupling responses during exercise. Exercise capacity and symptoms of exertional intolerance were correlated with abnormalities in each component of cardiovascular reserve function, and HFpEF subjects were more likely to display multiple abnormalities in reserve.
CONCLUSIONS: HFpEF is characterized by depressed reserve capacity involving multiple domains of cardiovascular function, which contribute in an integrated fashion to produce exercise limitation. Appreciation of the global nature of reserve dysfunction in HFpEF will better inform optimal design for future diagnostic and therapeutic strategies.
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20813282      PMCID: PMC2950645          DOI: 10.1016/j.jacc.2010.03.077

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  31 in total

1.  Trends in prevalence and outcome of heart failure with preserved ejection fraction.

Authors:  Theophilus E Owan; David O Hodge; Regina M Herges; Steven J Jacobsen; Veronique L Roger; Margaret M Redfield
Journal:  N Engl J Med       Date:  2006-07-20       Impact factor: 91.245

2.  Exercise-induced vasodilation in forearm circulation of normal subjects and patients with congestive heart failure: role of endothelium-derived nitric oxide.

Authors:  S D Katz; H Krum; T Khan; M Knecht
Journal:  J Am Coll Cardiol       Date:  1996-09       Impact factor: 24.094

3.  Ventricular systolic assessment in patients with dilated cardiomyopathy by preload-adjusted maximal power. Validation and noninvasive application.

Authors:  T Sharir; M D Feldman; H Haber; A M Feldman; A Marmor; L C Becker; D A Kass
Journal:  Circulation       Date:  1994-05       Impact factor: 29.690

4.  Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans.

Authors:  Barry A Borlaug; Vojtech Melenovsky; Tricia Marhin; Patricia Fitzgerald; David A Kass
Journal:  Circulation       Date:  2005-10-25       Impact factor: 29.690

5.  Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism.

Authors:  D W Kitzman; M B Higginbotham; F R Cobb; K H Sheikh; M J Sullivan
Journal:  J Am Coll Cardiol       Date:  1991-04       Impact factor: 24.094

6.  Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium.

Authors:  Craig S Smith; Paul A Bottomley; Steven P Schulman; Gary Gerstenblith; Robert G Weiss
Journal:  Circulation       Date:  2006-09-04       Impact factor: 29.690

7.  Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia.

Authors:  Piero O Bonetti; Geralyn M Pumper; Stuart T Higano; David R Holmes; Jeffrey T Kuvin; Amir Lerman
Journal:  J Am Coll Cardiol       Date:  2004-12-07       Impact factor: 24.094

8.  Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure.

Authors:  Catalin F Baicu; Michael R Zile; Gerard P Aurigemma; William H Gaasch
Journal:  Circulation       Date:  2005-04-25       Impact factor: 29.690

9.  Diminished contractile response to increased heart rate in intact human left ventricular hypertrophy. Systolic versus diastolic determinants.

Authors:  C P Liu; C T Ting; W Lawrence; W L Maughan; M S Chang; D A Kass
Journal:  Circulation       Date:  1993-10       Impact factor: 29.690

10.  Endothelium-dependent vasodilation is attenuated in patients with heart failure.

Authors:  S H Kubo; T S Rector; A J Bank; R E Williams; S M Heifetz
Journal:  Circulation       Date:  1991-10       Impact factor: 29.690

View more
  219 in total

Review 1.  Endothelial dysfunction and coronary artery disease: assessment, prognosis, and treatment.

Authors:  Yasushi Matsuzawa; Amir Lerman
Journal:  Coron Artery Dis       Date:  2014-12       Impact factor: 1.439

Review 2.  Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials.

Authors:  Ambarish Pandey; Akhil Parashar; Dharam Kumbhani; Sunil Agarwal; Jalaj Garg; Dalane Kitzman; Benjamin Levine; Mark Drazner; Jarett Berry
Journal:  Circ Heart Fail       Date:  2014-11-16       Impact factor: 8.790

3.  Use of the Frank-Starling mechanism during exercise is linked to exercise-induced changes in arterial load.

Authors:  Paul D Chantler; Vojtech Melenovsky; Steven P Schulman; Gary Gerstenblith; Lewis C Becker; Luigi Ferrucci; Jerome L Fleg; Edward G Lakatta; Samer S Najjar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-10-14       Impact factor: 4.733

4.  Can Oxygen Transport Analysis Tell Us Why People With Heart Failure With Preserved Ejection Fraction Feel So Poorly?

Authors:  Barry A Borlaug
Journal:  Circulation       Date:  2018-01-09       Impact factor: 29.690

Review 5.  Deep Phenotyping of Systemic Arterial Hemodynamics in HFpEF (Part 2): Clinical and Therapeutic Considerations.

Authors:  Julio A Chirinos
Journal:  J Cardiovasc Transl Res       Date:  2017-04-11       Impact factor: 4.132

6.  Measures of Ventricular-Arterial Coupling and Incident Heart Failure With Preserved Ejection Fraction: A Matched Case-Control Analysis.

Authors:  Carolyn L Lekavich; Debra J Barksdale; Jia-Rong Wu; Virginia Neelon; Jamie Crandell; Eric J Velazquez
Journal:  J Card Fail       Date:  2017-07-14       Impact factor: 5.712

7.  Myocardial Energetics in Heart Failure With Preserved Ejection Fraction.

Authors:  Omar F AbouEzzeddine; Bradley J Kemp; Barry A Borlaug; Brian P Mullan; Atta Behfar; Sorin V Pislaru; Marat Fudim; Margaret M Redfield; Panithaya Chareonthaitawee
Journal:  Circ Heart Fail       Date:  2019-10-15       Impact factor: 8.790

Review 8.  Current Management and Future Directions of Heart Failure With Preserved Ejection Fraction: a Contemporary Review.

Authors:  Chayakrit Krittanawong; Marrick L Kukin
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-20

Review 9.  Determinants of exercise intolerance in patients with heart failure and reduced or preserved ejection fraction.

Authors:  Mark J Haykowsky; Corey R Tomczak; Jessica M Scott; D Ian Paterson; Dalane W Kitzman
Journal:  J Appl Physiol (1985)       Date:  2015-04-24

10.  Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction.

Authors:  Muaz M Abudiab; Margaret M Redfield; Vojtech Melenovsky; Thomas P Olson; David A Kass; Bruce D Johnson; Barry A Borlaug
Journal:  Eur J Heart Fail       Date:  2013-02-20       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.